Orbimed Advisors LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1055951) · Explore on the interactive board
Orbimed Advisors LLC disclosed 121 US equity positions worth $5.3bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is EWTX at 11.9% of the reported book, followed by ELVN, LLY. The top ten holdings are 43.0% of the book, and the portfolio behaves like about 31 equal-weight positions. Versus the prior filing it opened 35 new positions, added to 32, reduced 26 and exited 21. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Orbimed Advisors LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 35 new, 32 added, 26 reduced, 21 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 11.9% | $630.5m | 15,518,492 | 0% | held |
| 2 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.5% | $343.9m | 6,776,632 | -15% | reduced |
| 3 | LLY ELI LILLY & CO | Healthcare | 5.9% | $309.3m | 257,900 | 9% | added |
| 4 | MBX MBX BIOSCIENCES INC | Healthcare | 3.6% | $189.3m | 3,428,736 | -6% | reduced |
| 5 | SVA SINOVAC BIOTECH LTD | 3.5% | $184.5m | 2,718,735 | 0% | held | |
| 6 | AZN ASTRAZENECA PLC | Healthcare | 3.2% | $171.1m | 915,700 | 37% | added |
| 7 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.2% | $118.6m | 2,209,400 | 50% | added |
| 8 | SION SIONNA THERAPEUTICS INC | Healthcare | 2.1% | $112.4m | 2,555,877 | -28% | reduced |
| 9 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 2.0% | $107.0m | 7,165,006 | 0% | held |
| 10 | AVBP ARRIVENT BIOPHARMA INC | Healthcare | 2.0% | $105.2m | 3,027,328 | 0% | held |
| 11 | GH GUARDANT HEALTH INC | Healthcare | 1.7% | $87.6m | 583,700 | 34% | added |
| 12 | ARGX ARGENX SE | Healthcare | 1.6% | $86.2m | 92,880 | -32% | reduced |
| 13 | MRK MERCK & CO INC | Healthcare | 1.6% | $85.2m | 663,400 | 0% | held |
| 14 | UNIQURE NV | 1.6% | $83.3m | 1,807,486 | -15% | reduced | |
| 15 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.5% | $77.0m | 230,100 | 33% | added |
| 16 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 1.4% | $75.5m | 834,900 | -32% | reduced |
| 17 | PRLD PRELUDE THERAPEUTICS INC | 1.4% | $73.2m | 13,724,571 | 26% | added | |
| 18 | ABVX ABIVAX SA | Healthcare | 1.4% | $72.8m | 546,522 | 17% | added |
| 19 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.4% | $71.9m | 3,235,684 | 11% | added |
| 20 | NTRA NATERA INC | Healthcare | 1.3% | $71.1m | 262,000 | 0% | held |
| 21 | CGON CG ONCOLOGY INC | Healthcare | 1.3% | $69.1m | 972,800 | 3% | added |
| 22 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.3% | $67.0m | 161,100 | – | new |
| 23 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.3% | $66.4m | 8,288,510 | 0% | held |
| 24 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.2% | $65.2m | 244,456 | – | new |
| 25 | HUM HUMANA INC | Healthcare | 1.2% | $65.2m | 164,100 | – | new |
| 26 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.2% | $65.1m | 1,681,300 | 422% | added |
| 27 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.2% | $63.3m | 1,483,200 | -38% | reduced |
| 28 | ISRG INTUITIVE SURGICAL INC | Healthcare | 1.2% | $62.8m | 157,900 | -24% | reduced |
| 29 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.1% | $56.9m | 2,110,300 | 3% | added |
| 30 | ODYSSEY THERAPEUTICS INC | 1.1% | $56.2m | 3,001,198 | – | new | |
| 31 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.0% | $53.9m | 892,471 | -16% | reduced |
| 32 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.0% | $53.5m | 2,042,000 | – | new |
| 33 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 1.0% | $53.3m | 925,000 | 0% | held |
| 34 | QTTB Q32 BIO INC | 1.0% | $52.6m | 4,127,987 | 83% | added | |
| 35 | SYK STRYKER CORPORATION | Healthcare | 0.9% | $50.1m | 159,100 | -13% | reduced |
| 36 | CAI CARIS LIFE SCIENCES INC | Healthcare | 0.9% | $50.0m | 2,806,811 | 0% | held |
| 37 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 0.9% | $45.5m | 90,700 | 95% | added |
| 38 | PVLA PALVELLA THERAPEUTICS INC NE | Healthcare | 0.8% | $44.7m | 292,360 | 117% | added |
| 39 | ELV ELEVANCE HEALTH INC FORMERLY | Healthcare | 0.8% | $44.4m | 114,700 | 0% | held |
| 40 | STTK SHATTUCK LABS INC | Healthcare | 0.8% | $43.8m | 6,306,127 | 0% | held |
| 41 | UPB UPSTREAM BIO INC | 0.7% | $39.4m | 5,693,589 | 0% | held | |
| 42 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.7% | $37.4m | 999,000 | 0% | held | |
| 43 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 0.7% | $35.9m | 322,900 | 3% | added |
| 44 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.6% | $33.7m | 1,542,000 | 60% | added |
| 45 | FBRX FORTE BIOSCIENCES INC | 0.6% | $33.5m | 1,577,705 | 32% | added | |
| 46 | CMPX COMPASS THERAPEUTICS INC | 0.6% | $33.3m | 15,219,994 | 0% | held | |
| 47 | NKTR NEKTAR THERAPEUTICS | Healthcare | 0.6% | $32.5m | 465,346 | 69% | added |
| 48 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.6% | $30.9m | 83,200 | 20% | added |
| 49 | PRELUDE THERAPEUTICS INC | 0.6% | $30.3m | 5,680,186 | -9% | reduced | |
| 50 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 0.5% | $28.8m | 117,578 | -45% | reduced |
What did Orbimed Advisors LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| MYGN MYRIAD GENETICS INC | 26.7% | $122.9m |
| PFE PFIZER INC | 11.9% | $54.7m |
| DHR DANAHER CORP DEL | 11.0% | $50.4m |
| RCEL AVITA MEDICAL INC | 9.3% | $42.5m |
| ASND ASCENDIS PHARMA A/S | 9.1% | $41.6m |
| ESPERION THERAPEUTICS INC NE | 6.3% | $29.0m |
| BTSG BRIGHTSPRING HEALTH SVCS INC | 4.6% | $21.2m |
| AMGN AMGEN INC | 3.1% | $14.0m |
| ALHC ALIGNMENT HEALTHCARE INC | 3.0% | $13.9m |
| REGN REGENERON PHARMACEUTICALS | 2.5% | $11.4m |
| CARL CARLSMED INC | 2.5% | $11.3m |
| GILD GILEAD SCIENCES INC | 1.8% | $8.3m |
| HRTX HERON THERAPEUTICS INC | 1.7% | $7.9m |
| AVTX AVALO THERAPEUTICS INC | 1.5% | $7.1m |
| CMPS COMPASS PATHWAYS PLC | 1.4% | $6.4m |
| ADCT ADC THERAPEUTICS SA | 1.1% | $4.9m |
| CGEM CULLINAN THERAPEUTICS INC | 0.8% | $3.5m |
| JBIO JADE BIOSCIENCES INC | 0.6% | $2.6m |
| CCCC C4 THERAPEUTICS INC | 0.5% | $2.3m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 0.4% | $1.9m |
| VTGN VISTAGEN THERAPEUTICS INC | 0.4% | $1.7m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 84.5% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Orbimed Advisors LLC's portfolio?
Across every quarter Orbimed Advisors LLC has filed, its median largest position is 11.3% of the book and its median top-ten weight is 42.9%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 20.0 completed holding spells, the median lasted 1.0 quarters; 121.0 positions are still open and their final length is unknown.